NCT06268561招募中不适用
Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Visual acuity
研究概览
简要总结
OZURDEX endophthalmitis is a rare and potentially very serious pathology. Different treatments can be carried out early and change the functional prognosis of the patient.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who had endophtalmitis following an OZURDEX implant injection within 2 months
排除标准
- •Intra oculaire procedure in the interval between the injection of OZURDEX and endophtalmitis
结局指标
主要结局
Visual acuity
时间窗: 2018 to 2023
Evolution of visual acuity from the first to the last patient includes
次要结局
- Tomography(2018 to 2023)
- IOP measured in mmHg by tonometer and confirmed with Goldman Applanation(2018 to 2023)
- Resumption of intravitreal therapy(2018 to 2023)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Anatomic Outcomes Following Ozurdex InjectionsRetinal Vein OcclusionsNCT01282411Barnes Retina Institute10
进行中（未招募）
1 期
sing an anti inflammatory eye implant (Ozurdex) to help improve surgical outcomes in patients with scar tissue (PVR) on the retinaMedDRA version: 14.0 Level: PT Classification code 10038934 Term: Retinopathy proliferative System Organ Class: 10015919 - Eye disordersProliferative VitreoretinopathyEUCTR2011-004498-96-GBMoorfields Eye Hospital140
已完成
不适用
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX StudyDiabetic Macular OedemaNCT02731911Allergan202
已完成
4 期
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein OcclusionMacular EdemaRetinal Vein OcclusionNCT01903720Allergan71
撤回
4 期
Ozurdex Monotherapy TrialUveitis, PosteriorUveitis, IntermediatePanuveitisNCT05101928Ottawa Hospital Research Institute84